Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

More Disheartening News For Abbott Cholesterol Franchise: Niaspan/Statin Study Halted Due To Lack Of Added Benefit

This article was originally published in The Pink Sheet Daily

Executive Summary

NIH's early termination of the AIM-HIGH trial does further damage to combination therapy for increasing HDL cholesterol and lowering triglycerides in patients with well-controlled LDL cholesterol.
Advertisement

Related Content

Merck Calls It Quits On Anacetrapib
Merck Calls It Quits On Anacetrapib
New Cholesterol Guidelines Follow Long History Of Failed Outcomes Trials
Cholesterol Guidelines Look High And Low: Statin Market Extended At Both Ends
GSK’s Darapladib Poised To Become Latest Cardiovascular Outcomes Casualty
Cholesterol Drug Approvals May Hinge On Outcomes Studies; FDA Rejects Diabetes-style Tiered Trials
Phase II Preview For Roche's Dalcetrapib May Give CETP Inhibition A Boost
Trilipix Advisory Committee Call For Outcomes Trial Could Be Damaged By Niaspan Failure
Could ACCORD Results Mean Another Trial For Trilipix?
Could ACCORD Results Mean Another Trial For Trilipix?

Topics

What to read next

Advertisement
UsernamePublicRestriction

Register

PS072294

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel